Medium cut‑off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin‑independent manner in maintenance hemodialysis patients: results from a randomized controlled trial
- "MCO group showed different change from baseline to 12 weeks in ESA dose (−3135 ± 4836 vs. +560 ± 5090 U/wk, p = 0.012), in weight-adjusted ESA (−49.8 ± 81.6 vs.+ 8.1 ± 90.2 U/kg/wk, p = 0.023), and in ERI (−5.2 ± 7.8 vs. +0.1 ± 9.1 U/kg/wk/g/dL, p = 0.034).
MCO group showed a greater reduction in TNF-α and lower serum TNF-α level"